SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 120.06 |
| Enterprise Value ($M) | 97.54 |
| Book Value ($M) | 55.69 |
| Book Value / Share | 0.31 |
| Price / Book | 2.16 |
| NCAV ($M) | 11.30 |
| NCAV / Share | 0.06 |
| Price / NCAV | 10.62 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -1.03 |
| Return on Assets (ROA) | -0.67 |
| Return on Equity (ROE) | -0.96 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 3.14 |
| Current Ratio | 3.14 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 44.28 |
| Assets | 88.67 |
| Liabilities | 32.98 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 7.38 |
| Operating Income | -83.35 |
| Net Income | -82.47 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -70.45 |
| Cash from Investing | 43.95 |
| Cash from Financing | 15.24 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Vanguard Group Inc | 4.63 | 0.36 | |
| 13G | Ra Capital Management, L.p. | 9.10 | ||
| 13G/A | BlackRock Inc. | 1.30 | -78.23 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 291,543 | 1,200,054 | 24.29 | |
| 425,522 | 1,176,394 | 36.17 | |
| 199,875 | 813,651 | 24.57 | |
| 237,031 | 632,726 | 37.46 | |
| 177,251 | 753,416 | 23.53 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| VSTM – Verastem, Inc. | VTGN – Vistagen Therapeutics, Inc. |
| VTVT – vTv Therapeutics Inc. | VYNE – VYNE Therapeutics Inc. |
| WINT – Windtree Therapeutics, Inc. |